FDA approves new migraine medication

Research we're watching

If you suffer from migraine headaches, there's a new option available to relieve your pain. In October 2019, the FDA approved lasmiditan (Reyvow) to treat migraine pain in adults. Taken as a pill, it works for migraines either with or without an aura (a visual disturbance within the hour before migraine pain starts). Lasmiditan is not designed to prevent migraines. Lasmiditan is the first migraine treatment in a class of drugs known as serotonin (5-HT) 1F receptor agonists. In studies, researchers found that it could relieve pain and other migraine symptoms within two hours.

Migraines affect an estimated 28 million women in the United States, according to the American Migraine Foundation, and the World Health Organization ranks them among the top 10 disabling conditions. Pain and other symptoms, which may include nausea, sensitivity to light and temporary vision changes, result in lost work days, reduced productivity, and diminished quality of life for many people.

Image: Cecilie_Arcurs/Getty Images

Disclaimer:
As a service to our readers, Harvard Health Publishing provides access to our library of archived content. Please note the date of last review on all articles. No content on this site, regardless of date, should ever be used as a substitute for direct medical advice from your doctor or other qualified clinician.